Doro AB

  • ISIN: SE0000215493
  • Land: .

Nachricht vom 21.03.2012 | 17:00

Bulletin from Doro AB’s Annual General Meeting 2012


Doro AB 

21.03.2012 17:00

Lund, Sweden, 2012-03-21 17:00 CET (GLOBE NEWSWIRE) -- At the Annual General Meeting of Doro AB (publ), held on 21 March 2012, it was resolved, inter alia: * to adopt the income statement and balance sheet, and the consolidated income statement and the consolidated balance sheet; * to distribute a dividend of SEK 1 per share for the financial year 2011; * to discharge from liability the members of the board of directors and the CEO for the financial year 2011; * to re-elect Bo Kastensson, Karin Moberg, Jonas Mårtensson, Jérôme Arnaud and Charlotta Falvin as members of the board of directors for the period up to and including the next annual general meeting; * to re-elect Bo Kastensson as the chairman of the board of directors; * remuneration to the board as follows: the chairman receives SEK 350,000 and other members not employed by the company receive SEK 150,000 each; * to adopt principles for the appointment of the nomination committee; * to authorize the board, for the period until the next annual general meeting, to resolve, on one or several occasions, to issue not more than 1,930,000 shares without preferential rights for the shareholders. Such new issue resolution shall include a provision that new shares shall be paid in kind; and * to adopt remuneration guidelines with the principal effect that salaries and other terms of remuneration for the group management shall be on market terms. For more information, please contact: President and CEO Jérôme Arnaud, +46 (0)46 280 50 05, or Vice President and CFO Annette Borén, +46 (0)706 30 00 09. This is information that Doro AB (publ) is required to publish in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. This information was submitted for publication on March 21, 2012 at 5 p.m CET. News Source: NASDAQ OMX 21.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: Doro AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0000215493 WKN: End of Announcement DGAP News-Service

GBC im Fokus

Neovacs S.A.: Kurzfristige Potenziale durch Fast-Track-Zulassung möglich

Das in Frankreich ansässige Biotechnologieunternehmen Neovacs S.A. fokussiert sich auf die Entwicklung so genannter Kinoide, welche für die Behandlung von Autoimmunerkrankungen sowie entzündlichen Erkrankungen verwendet werden. Der Neovacs-Wirkstoff wird derzeit im Rahmen einer klinischen Studie IIb (SLE) in 19 Ländern (Europa, Asien, Lateinamerika, USA) an 178 Patienten untersucht. Wir rechnen mit den ersten Ergebnissen in Sommer 2017. Im Rahmen des DCF-Bewertungsmodells haben wir inkl. eines hohen Sicherheitsabschlages einen fairen Wert von2,90 € je Aktie ermittelt. Wir vergeben das Rating KAUFEN.

Aktueller Webcast

Mobimo Holding AG

Presentation of the interim results 2016

04. August 2016

Aktuelle Research-Studie

MOLOGEN AG

Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY

22. Juli 2016